Selective protein kinase inhibitors are powerful tools for interrogating cellular signaling pathways and validating drug targets for the treatment of a variety of cancers. The drug discovery paradigm that exists today starts with the identification and validation of kinase targets primarily at academic institutions followed by inhibitor development by the pharmaceutical sector. A major shortcoming of this paradigm is the severe shortage of selective inhibitors for most kinases hampers initial pharmacological proof-of-concept studies and therefore discourages further exploration of these targets by the pharmaceutical sector. Our laboratory has attempted to address this deficiency by developing efficient approaches to the discovery of first-in-class kinase inhibitors, which are then used as pharmacological 'tools' to investigate the functions and potential therapeutic relevance of the kinase in question. Over the last five years, our laboratory has developed and widely distributed the first inhibitors of ALK, Mps1, Erk5, mTor, LRRK2, FGFRs, JNKs, and the T790M mutant form of EGFR; several of which are currently standard reference compounds. In this application we have assembled a multidisciplinary team that integrates medicinal chemistry (Nathanael Gray), structural biology (Jane Endicott), transcription (Richard Young) and cancer biology and translational research (Constantine Mitsiades) that will enable the development and application of the first highly potent and selective inhibitors of CDK7. The cyclin-dependent kinases are a highly conserved class of protein kinases that consist of 20 members (CDK1-20) that associate with a family of 29 regulatory proteins called cyclins. They regulate a large number of cellular functions including cell cycle (CDK1-6), transcription (CDK7-13, 19), and splicing (CDK11). While the cell cycle regulating CDKs have received a significant amount of attention as drug discovery targets the so-called 'transcriptional CDKs' (tCDKs - CDK7-13, 19) have received much less. We have discovered an unprecedented means of developing selective CDK7 inhibitors by covalently targeting a unique cysteine (Cys) residue located outside of the kinase domain. We have obtained compelling preliminary data of the activity of CDK7 inhibitors in a large number of cancers, but here we propose to focus on investigating the potential of targeting CDK7 for the treatment of Multiple Myeloma, a plasma cell tumor where excess transcription is a hallmark of the disease and, based on our preliminary data, CDK7 plays a critical pathophysiological role. This will be accomplished through a focused medicinal chemistry campaign (Aim 1) and guided by detailed mechanistic characterization (Aim 2), followed by preclinical evaluation in cellular and murine models of Multiple Myeloma (Aim 3).

Public Health Relevance

Multiple Myeloma (MM) is the 2nd most commonly diagnosed hematologic cancer in the US and is currently incurable. We have identified a potential target called CDK7 that regulates the production of new proteins and this grant will develop prototype drugs directed against CDK7 and evaluate whether they are effective in preclinical MM models.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Forry, Suzanne L
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Dana-Farber Cancer Institute
United States
Zip Code
Deng, Jiehui; Wang, Eric S; Jenkins, Russell W et al. (2018) CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation. Cancer Discov 8:216-233
Terai, Hideki; Kitajima, Shunsuke; Potter, Danielle S et al. (2018) ER Stress Signaling Promotes the Survival of Cancer ""Persister Cells"" Tolerant to EGFR Tyrosine Kinase Inhibitors. Cancer Res 78:1044-1057
Rusan, Maria; Li, Kapsok; Li, Yvonne et al. (2018) Suppression of Adaptive Responses to Targeted Cancer Therapy by Transcriptional Repression. Cancer Discov 8:59-73
Olson, Calla M; Jiang, Baishan; Erb, Michael A et al. (2018) Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation. Nat Chem Biol 14:163-170
Zeng, Mei; Kwiatkowski, Nicholas P; Zhang, Tinghu et al. (2018) Targeting MYC dependency in ovarian cancer through inhibition of CDK7 and CDK12/13. Elife 7:
Kalan, Sampada; Amat, Ramon; Schachter, Miriam Merzel et al. (2017) Activation of the p53 Transcriptional Program Sensitizes Cancer Cells to Cdk7 Inhibitors. Cell Rep 21:467-481
Wong, Regina Wan Ju; Ngoc, Phuong Cao Thi; Leong, Wei Zhong et al. (2017) Enhancer profiling identifies critical cancer genes and characterizes cell identity in adult T-cell leukemia. Blood 130:2326-2338
Cayrol, Florencia; Praditsuktavorn, Pannee; Fernando, Tharu M et al. (2017) THZ1 targeting CDK7 suppresses STAT transcriptional activity and sensitizes T-cell lymphomas to BCL2 inhibitors. Nat Commun 8:14290
Mitsiades, Constantine S (2016) Tight Junction Protein 1: New Insights into Proteasome Inhibitor Resistance and Myeloma Pathophysiology. Cancer Cell 29:611-612
Zhang, Tinghu; Kwiatkowski, Nicholas; Olson, Calla M et al. (2016) Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors. Nat Chem Biol 12:876-84

Showing the most recent 10 out of 17 publications